Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,550 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06268652RecruitingPhase 3
Personalized treatment guided by lab-grown tumor samples for advanced breast cancer
This trial tests whether using a personalized approach—growing your tumor cells in the lab to find the best treatment—can work better than standard treatments chosen by your doctor. It is for people with advanced breast cancer that has stopped responding to at least two previous treatments.
Guangzhou, None SelectedAges 18 years+ - NCT06223841RecruitingPhase 1/Phase 2
Testing IAP0971 for advanced solid tumors and lung cancer
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT05999149RecruitingPhase 3
Famitinib plus chemo and immunotherapy before breast cancer surgery
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07854600RecruitingPhase 2
Ivonescimab plus chemotherapy before surgery for bile duct cancer
This trial tests a new drug combination given before surgery to shrink bile duct cancer tumors, potentially making surgery more successful. It is for patients whose cancer is locally advanced or has spread to only a few places.
Beijing, Beijing MunicipalityAges 18–80 - NCT06101082RecruitingPhase 1
Testing anti-HER2-CAR-T cells for advanced solid tumors
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
Shenyang, LiaoningAges 18–70 - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120 - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT06223256RecruitingPhase 1
NBL-028 for advanced solid tumors with CLDN6
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
Shijiazhuang, HebeiAges 18 years+ - NCT05883800Recruiting
Total treatment with tailored radiation for advanced rectal cancer
This study tests a “total neoadjuvant” approach—chemotherapy first, then radiation—using adaptive (tailored) radiation planning for people with locally advanced rectal cancer. It may help improve tumor control while adjusting the radiation based on how your cancer and anatomy respond.
BergenAges 18 years+ - NCT06103630Recruiting
Mouth exercises for sleep apnea with mouthguard therapy
This study tests whether specific mouth and throat exercises can help people with sleep apnea who already use a mandibular advancement device (a type of mouthguard). The goal is to see if adding exercises improves sleep and breathing.
TainanAges 20 years+ - NCT05217407Recruiting
Registry study for people with rare or advanced cancers
This is a study that collects information about people with rare cancers (or cancers where the source is unknown) and advanced-stage cancer. It helps researchers build a knowledge database to improve understanding and care for these cancers in Asia.
Chuo-ku, TokyoAges 18 years+ - NCT05877924RecruitingPhase 1
Early-phase study of an injected cancer treatment for advanced tumors
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Guanzhou, GuangdongAges 18 years+ - NCT06338332Recruiting
Stent before surgery for right-sided colon blockage from cancer
This trial tests whether placing a stent first to relieve a blockage in the right side of the colon improves outcomes before surgery for colon cancer. It aims to help patients who come to the hospital with a blocked colon due to cancer.
Breda, North BrabantAges 18 years+ - NCT06343077RecruitingPhase 2
Hiltonol injection for prostate cancer on active surveillance
This trial tests a drug called Hiltonol (Poly-ICLC) given directly into the prostate tumor along with an injection under the skin. It is for men with low-risk prostate cancer who are on active surveillance, to see if the drug can slow or stop the cancer from growing.
New York, New YorkAges 18 years+ - NCT05263479RecruitingPhase 1
Study drug for advanced solid tumors that can’t be treated
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06221748RecruitingPhase 2/Phase 3
Study of DV with cadonilimab for HER2-positive stomach cancer
This trial tests a combination of two drugs (DV and cadonilimab) for people with HER2-positive stomach or gastroesophageal junction cancer that has grown after first treatment. It aims to see if this combo can help when standard options have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT02799537Recruiting
Compare a new end-of-life letter to advance directives
This study compares two ways of sharing your end-of-life wishes: a “Stanford Letter Project” form versus traditional advance directives. If you’re an adult, your answers may help the researchers see which option is easier to use or better understood.
Stanford, CaliforniaAges 18 years+ - NCT06336187Recruiting
Active monitoring for small kidney tumors
This study tests whether closely monitoring small kidney tumors (less than 4 cm) with regular imaging is a safe and effective option for people who cannot or choose not to have immediate treatment. It involves a biopsy at the start to confirm the tumor type.
NovaraAges 18 years+ - NCT06371586RecruitingPhase 2
Neo-Sequence 2: New drug combo for advanced stomach cancer
This trial tests a new treatment plan for advanced stomach cancer using chemotherapy, anti-angiogenesis therapy (to cut off tumor blood supply), and immunotherapy (to help your immune system fight cancer). The goal is to see if this combination works better before surgery.
BeijingAges 18–75 - NCT06363825RecruitingPhase 2
New combination therapy for advanced liver cancer
This trial tests a combination of treatments for advanced liver cancer: a targeted therapy (apatinib), an immunotherapy (camrelizumab), and two local treatments (TAE and HAIC). It may be an option if you have a high tumor burden or a tumor thrombus in the portal vein and haven't had systemic treatment before.
FuzhouAges 18–80 - NCT04204837RecruitingPhase 2
Nivolumab for advanced skin squamous cell cancer
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
GrazAges 18 years+ - NCT05738616RecruitingPhase 3
Testing lenvatinib plus TACE and immunotherapy before liver surgery
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Chengdu, SichuanAges 18–75 - NCT05909241RecruitingPhase 1
First study of BA1202 for advanced solid tumors
This Phase 1 study tests BA1202 in people with advanced solid cancers to find safe dosing and how the treatment may work. You may qualify if your cancer has progressed or you cannot use standard treatment, and—depending on the group—your tumor shows a specific marker called CEACAM5.
BeijingAges 18–70 - NCT05345587Recruiting
Digital monitoring plus proactive medication review during oral cancer treatment
This trial tests whether combining regular medication safety checks with electronic tracking of side effects can improve quality of life and help reduce economic burden for people taking cancer pills. It’s for people starting oral cancer therapy and using connected technology to report symptoms.
Brive-la-GaillardeAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,550 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.